Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Denyo Adjoa Zakhia, MD Kristin Hunt Karner, MD Henry Ford Hospital, Detroit, MI 61 year-old Caucasian male Cough, night sweats, low-grade fever Complete blood count Hemoglobin – 9.4 gm/dl White blood cell count – 71.1 K/uL Platelet count – 135 K/uL Peripheral blood smear Leukocytosis with 79% blasts BONE MARROW ASPIRATE Cellularity ->95% Blasts-87% BONE BIOPSY H&E CD1a FLOW CYTOMETRY cyto CD3 FLOW CYTOMETRY SUMMARY Positive antigen panel Negative antigen panel cytoCD3 CD3 cytoTDT CD4 CD2 CD8 CD7 CD5 CD13 CD10 CD15 CD11b CD34 CD14 CD117 CD16 HLA-DR CD33 CD56 CD61 CD235a cytoCD79a cytoMPO CHROMOSOMAL ANALYSIS OF BONE MARROW ASPIRATE 46,XY,del(16)(q13)[6]/46,XY[14] FISH ANALYSIS No genetic abnormalities involving: MYC(8q24) BCL6(3q27) IGH-BCL2(14:18) API2-MALT1(11:18) BCR-ABL(9:22) MLL (11q23) Inv 16 WHAT IS THE DIAGNOSIS? EGIL WHO EGIL T-lineage: Score 3.5 Myeloid: Score 2.5 - Mixed phenotype acute leukemia, favor T/myeloid WHO table (criteria) Myeloid lineage Myeloperoxidase (flow cytometry, immunohistochemistry or cytochemistry) Or Monocytic differentiation (at least too of NSE, CD11c, CD14, CD64, lysozyme) T lineage Cytoplasmic CD3 or Surface CD3 B lineage Strong CD19 with at least one of the following strongly expressed (CD79a, cytoplasmic CD22, CD10) Or Weak CD19 with at least two of the following strongly expressed (CD79a, cytoplasmic CD22, CD10) - Acute leukemia of T-cell Lineage with aberrant myeloid differentiation INITIAL PROPOSED DIAGNOSIS - Mixed phenotype acute leukemia, favor T/myeloid Acute leukemia of T-cell Lineage with aberrant myeloid differentiation PANEL CONSENSUS DIAGNOSIS EARLY T-CELL PRECURSOR ALL with MYELOID ANTIGEN EXPRESSION *NEED FOR A CONSENSUS IN THE CLASSIFICATION SYSTEM *Provide appropriate treatment *Provide appropriate prognostication Treatment and Outcome Hyper CVAD therapy Matched unrelated donor stem cell transplant Complications DVT New diagnosis of Hepatitis C infection Clostridium difficile colitis Reactivation of EBV and BK virus Subdural hemorrhage Patient in remission at day 116+ s/p SCT IMMUNOPHENOTYPE (Adapted from WHO 2008) CD7 CD1a CD2/CD5 CD3 CD4/CD8 Cytoplasmic | Double + Surface CD4+ CD8+ TdT T-ALL Early Mature Comprises 85-90% of all lymphoblastic lymphoma Adolescents > Younger children 15% pediatric ALL 25% adult ALL Presentation: Mediastinal mass with pleura effusions Bone marrow involvement if present <20% High peripheral blood blast counts CLINICAL SIGNIFICANCE OF ETP-ALL Clinical, laboratory and biologic characteristics not useful in prognostication HIGH RISK INDUCTION FAILURE EARLY RELAPSE CNS RELAPSE Children treated as high risk 75% 5 yr-event free survival rate (similar to pre B-ALL/LBL) DOES MYELOID ANTIGEN EXPRESSION OFFER ANY CLINICAL SIGNIFICANCE? •Asnafi et al •CD13 and CD33 most frequently expressed myeloid-associated antigens •15% of 91 cases reviewed •MPO – negative or very rarely <3% •Uckun et al •Not an adverse prognostic factor in childhood ALL Evaluated c-kit expression in 295 ALL patients and in 977 AML patients T- ALL, 5.4 % expressed c-kit In AML 84% expressed c-kit Concluded High c-kit expression is an independent predictor of Lower complete response in ALL Higher complete response in AML Not an independent predictor of disease free survival in ALL or AML T-ALL may benefit from AML type therapy •Improved survival rates •Normal karyotype •T(10:14)(q24:q11) HOX11:TCRα •Overexpression of HOX11 gene * REFERENCES •Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana- Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:36163622. •Onciu M, Lai R, Vega F, et al. Precursor T-cell acute lymphoblastic leukemia in adults: age-related immunophenotypic, cytogenetic, and molecular subsets. Am J Clin Pathol. 2002;117:252-258. •Brunning R, Borowitz M, Matutes E, et al. Precursor B-cell and T-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:109-117. World Health Organization Classification of Tumors. •Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, et al. The immunophenotype of 325 adult acute leukemias’: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol. 2002;117:380-389. •Asnafi V, Beldjord K, Libura M, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004;104:4173-4180. •Asnafi V, Buzyn A, Thomas X, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005;105:3072-3078. •Uckun FM, Sather HN, Gaynon PS, et al. Clinical feature and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 1997;90:28-35. •Tsao AS, Kantarjian H, Thomas D, et al. C-kit receptor expression in acute leukemias: association with patient and disease characteristics and with outcome. Leuk Res. 2004;28:373-378. •Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004;363:535-536. •Schneider NR, Carroll AJ, Shuster JJ, et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases. Blood. 2000;96:2543-2549. •X Han, CE Bueso-Ramos. Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J of clin pathol 2007;127:528-544. •Bene MC, Bernier RO, Casasnovas G, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid Leukemias and Undifferentiated leukemias. Blood 1998;15:596-599.